NewAmsterdam Pharma Company N.V., una compañía biofarmacéutica en fase avanzada, desarrolla terapias para mejorar la atención al paciente en poblaciones con enfermedad ...
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company dedicated to improving patient care for populations suffering from cardiometabolic diseases. Its primary focus is on developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, which is in clinical trials as a monotherapy and in combination with ezetimibe to lower LDL-C (bad cholesterol) for cardiovascular diseases. The company is also exploring Obicetrapib for Alzheimer's disease (Phase 2a trial). Founded in 2019 by renowned lipidologist Professor Dr. John Kastelein and venture capital firm Forbion, the company has raised significant funding, including a $196M (€160M) Series A round. With approximately 100 employees, NewAmsterdam Pharma is headquartered in Naarden, the Netherlands, and went public in February 2021 on NASDAQ. The company's CEO is Dr. Michael Davidson, a leading lipidologist and cardiologist, who joined in 2020. As of the latest data, the company has a market cap of about $3.27 billion and is actively trading. Financially, the company is in the clinical stage, with no revenue yet, and is currently unprofitable, but holds a strong cash position of approximately $5.14 per share. The company's operating metrics show significant R&D and SG&A expenses relative to minimal revenue, but with a solid current ratio of 9.03, indicating good liquidity. The company's mission is to address high unmet needs in lipid management, and it continues to advance its clinical programs, presenting at major lipid association meetings.
Piramal Pharma Solutions (Piramal Pharma Ltd)NSE:PPLPHARMAUnnamed CDMO (Canada-based)Unnamed CDMO (Austria-based)Unnamed CDMO (US-based, not Piramal)API Raw Material Suppliers (via Piramal Pharma Solutions network)Ezetimibe API Suppliers (generic drug substance)
Downstream
4
A. Menarini International Licensing S.A. (Menarini Group)Menarini Group (EU Distribution Network)US Market (Direct Commercialization – Planned)Japan Partner (Phase 2 Study Initiated)
